

*OK TO
CANCEL
HS 5-12-03*

IN THE CLAIMS:

Please cancel claim 14. Please amend claim 2 as follows:

1. (Previously Amended) A DNA-construct for the tissue-specific expression of a blood coagulation factor comprising a DNA sequence coding for an amino acid sequence of a blood coagulation factor and a DNA sequence functioning as a promoter which is specific for expression in hematopoietic cells.
2. (Currently Amended) The DNA-construct as claimed in claim 8, wherein the DNA sequence functioning as a promoter is the DNA sequence **coding** for the human platelet glycoprotein IIb (GPIIb) promoter.
3. (Previously Amended) The DNA-construct as claimed in claim 8 wherein the blood coagulation factor is Factor IX.
4. (Previously Amended) The DNA-construct as claimed in claim 8, wherein a first truncated intron (Intron 1) of the human FIX gene is inserted into the DNA sequence coding for an amino acid sequence of a blood coagulation factor.
5. (Previously Amended) A process for the production of Factor IX in hematopoietic cells comprising:
 - transfecting hematopoietic cells with the DNA-construct of claim 3 and

-expressing the DNA-construct in the hematopoietic cells.

6. (Previously Amended) The process as claimed in claim 14, wherein the production of Factor IX is stimulated by an inducer.

7. (Previously Amended) The process as claimed in claim 6, wherein the inducer is phorbol-12-myristate-13-acetate (PMA).

8. (Previously Amended) The DNA-construct according to claim 1 wherein the hematopoietic cells are megakaryocytes.

9. (Previously Added) A process for the production of a blood coagulation factor in a hematopoietic cell line comprising:

- transfecting hematopoietic cells with a DNA-construct coding for a blood coagulation factor comprising:
 - a DNA sequence coding for the amino acid sequence of a blood coagulation factor; and
 - a DNA sequence functioning as a promoter which is specific for expression in hematopoietic cells; and
- expressing the DNA-construct.

10. (Previously Added) The process as claimed in claim 9, wherein the production of the blood coagulation factor is stimulated by an inducer.

11. (Previously Added) The process as claimed in claim 10, wherein the inducer is phorbol-12-myristate-13-acetate (PMA).

12. (Previously Amended) The process according to claim 9 wherein the DNA sequence functioning as a promoter is the DNA sequence for the human platelet glycoprotein IIb (GPIIb) promoter.

13. (Previously Amended) The process according to claim 9 wherein the hematopoietic cells are megakaryocytes.

14. (Canceled) The process according to claim 5 wherein the hematopoietic cells are megakaryocytes.

REMARKS

Claim 14 has been canceled. Claim 2 has been amended to more clearly define the claimed invention. Support for the amendment to claim 2 can be found in the specification, thus no new matter has been added. Claims 1-13 are currently pending. The above amendments and following remarks place the claims in condition for allowance or in better condition for appeal. Applicants, therefore, respectfully request entry of this Amendment and Response, and reconsideration in light thereof.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com